Recently, mesothelin-targeted agents, such as the secreted phosphoprotein 1 (SS1P) immunotoxin and anti-mesothelin chimeric antigen receptor (CAR)-T cells, have entered clinical trials for mesothelioma and ovarian cancer [22]. Here, MSLN is linked to ovarian carcinoma.